Bristol Myers Squibb manufactures prescription pharmaceuticals and biologics in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis, and psychiatric disorders.
The company’s milestones:
1858: The Squibb corporation was founded by Edward Robinson Squibb in Brooklyn, New York.
1882: Dr. Squibb introduces a bi-monthly publication called Ephemeris. Written for physicians, the magazine offers information on new pharmaceutical developments.
1887: Hamilton College graduates William McLaren Bristol and John Ripley Myers purchased the Clinton Pharmaceutical company in Clinton, New York.
May 1898: They decided to rename it Bristol, Myers and Company.
1892: Dr. Squibb forms a partnership with his sons, Edward and Charles, and the firm is renamed E.R Squibb & Sons.
1899: Bristol changed its name to the Bristol-Myers Corporation.
During the 1890s: Bristol-Myers Corporation introduced its first nationally recognized product Sal Hepatica, a laxative mineral salt, followed by Ipana toothpaste in 1901. Other divisions were Clairol (hair colors and haircare) and Drackett (household products such as Windex and Drano).
1902: E.R. Squibb & Sons established its first quality-control laboratory.
1914: Squibb Biological Laboratories division produces antitoxins, serums and vaccines.
1919: E.R. Squibb & Sons product line grows to 2,382 items sold in 6,547 packages, including newly-introduced veterinary medicines.
1944: Squibb opened the world's largest penicillin plant in New Brunswick, New Jersey.
1989: Bristol-Myers and Squibb merged and became Bristol-Myers Squibb.
1997: Bristol-Myers Squibb opens a 433-acre research campus in Hopewell, New Jersey.
1998: President Bill Clinton awards the National Medal of Technology — America’s highest honor for technological innovation — to Bristol-Myers Squibb "for extending and enhancing human life through innovative pharmaceutical research and development, and for redefining the science of clinical study through groundbreaking and hugely complex clinical trials that are recognized models in the industry."
1999: The Bristol Myers Squibb Foundation announces SECURE THE FUTURE, a $100 million commitment to advance HIV/AIDS research and community outreach programs in seven African countries.
2003: The first Children’s Clinical Center of Excellence—devoted to treating children with HIV/AIDS and their families—opens in Botswana.
2009: Bristol Myers Squibb acquires Medarex, Inc., a biotech company and a partner since 2005. The acquisition significantly expands the company’s oncology and immunology pipeline.
2015: Bristol-Myers Squibb is recognized as one of Dow Jones’ North America Index of Leading Sustainable Companies.
2019: Bristol-Myers Squibb and Celgene come together to create a leading biopharma company positioned to address the needs of patients with serious diseases.
2023: Bristol Myers Squibb (BMS) is investing $100 million in setting up its global science and technology Innovation centre in Hyderabad.
According to bms.com; en.wikipedia.org. Source of photos: internet